Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG

Yifan Zhou, Qiao Huang, Tingting Lu, Xiaobo Sun, Ling Fang, Zhengqi Lu, Xueqiang Hu, Allan Kermode, Wei Qiu

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

There is a lack of evidence for treatment of pediatric multiple sclerosis (PedMS). Treatment using azathioprine for PedMS has not been reported. A 10-year-old boy with multiple sclerosis who was seropositive for antibodies against myelin oligodendrocyte glycoprotein (MOG)-IgG was treated with azathioprine plus oral methylprednisolone. The patient showed clinical and magnetic resonance imaging stability, with MOG-IgG seroconversion. There were no major side effects over a 5-year period. Azathioprine may be a treatment option, particularly in poor medical resource areas, for pediatric patients with multiple sclerosis who are seropositive for MOG-IgG.

Original languageEnglish
Pages (from-to)71-73
Number of pages3
JournalJournal of Clinical Neuroscience
Volume38
DOIs
Publication statusPublished - 1 Apr 2017

Fingerprint Dive into the research topics of 'Azathioprine therapy in a case of pediatric multiple sclerosis that was seropositive for MOG-IgG'. Together they form a unique fingerprint.

Cite this